"Enzalutamide (Xtandi) is a type of hormone therapy that is already given to some people with prostate cancer that has spread to other parts of the body. But in new guidelines, the National Institute for Health and Care Excellence (NICE) rejected the drug for use in patients whose disease has stopped responding to other hormone treatments, but is less advanced and hasn't spread."
medicalxpress.com/news/2019...
-Patrick